Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFIBNASDAQ:ANGONASDAQ:ATRSNASDAQ:PLSENASDAQ:SRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFIBAcutus Medical$0.00$0.01$0.00▼$0.22$60K-0.3433,047 shsN/AANGOAngioDynamics$9.59+2.1%$9.87$5.47▼$13.50$389.42M0.6583,450 shs273,561 shsATRSAntares Pharma$5.59$5.59$3.11▼$5.60$955.06M1.153.29 million shs6 shsPLSEPulse Biosciences$14.80-3.4%$16.51$11.13▼$25.00$995.33M1.56184,907 shs99,122 shsSRDXSurmodics$29.99+3.4%$28.88$26.00▼$42.44$428.79M1.31229,119 shs140,852 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFIBAcutus Medical0.00%+11.11%+25.00%-94.87%-94.74%ANGOAngioDynamics+2.13%-2.84%-12.42%+5.27%+68.84%ATRSAntares Pharma0.00%0.00%0.00%0.00%0.00%PLSEPulse Biosciences-3.42%-0.63%-16.07%-1.88%+28.21%SRDXSurmodics+3.40%+3.08%+1.64%+2.27%-28.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFIBAcutus MedicalN/AN/AN/AN/AN/AN/AN/AN/AANGOAngioDynamics3.9967 of 5 stars3.51.00.04.22.51.70.6ATRSAntares PharmaN/AN/AN/AN/AN/AN/AN/AN/APLSEPulse Biosciences0.7469 of 5 stars0.00.00.04.20.04.20.0SRDXSurmodics4.2411 of 5 stars3.33.00.03.41.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFIBAcutus Medical 0.00N/AN/AN/AANGOAngioDynamics 3.00Buy$14.0045.99% UpsideATRSAntares Pharma 0.00N/AN/AN/APLSEPulse Biosciences 0.00N/AN/AN/ASRDXSurmodics 2.50Moderate Buy$43.0043.41% UpsideCurrent Analyst Ratings BreakdownLatest ANGO, ATRS, AFIB, PLSE, and SRDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025SRDXSurmodicsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/7/2025ANGOAngioDynamicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $16.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFIBAcutus Medical$7.16M0.01N/AN/A($0.03) per share-0.07ANGOAngioDynamics$283.32M1.37$4.38 per share2.19$5.13 per share1.87ATRSAntares Pharma$183.98M5.19$0.13 per share43.89$1.03 per share5.43PLSEPulse Biosciences$700K1,421.90N/AN/A$1.87 per share7.91SRDXSurmodics$126.08M3.40$0.32 per share93.73$8.33 per share3.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFIBAcutus Medical-$81.66MN/A0.00∞N/A-272.74%-311.64%-11.57%N/AANGOAngioDynamics-$184.35M-$1.01N/AN/AN/A-14.61%-3.73%-2.43%7/15/2025 (Estimated)ATRSAntares Pharma$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/APLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/14/2025 (Estimated)SRDXSurmodics-$11.54M-$1.39N/A37.48N/A-16.34%-7.10%-4.77%7/30/2025 (Estimated)Latest ANGO, ATRS, AFIB, PLSE, and SRDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q3 2025SRDXSurmodics-$0.21N/AN/AN/A$28.04 millionN/A7/15/2025Q4 2025ANGOAngioDynamics-$0.13N/AN/AN/A$74.26 millionN/A5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A4/30/2025Q2 2025SRDXSurmodics-$0.06-$0.13-$0.07-$0.36$32.23 million$28.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFIBAcutus MedicalN/AN/AN/AN/AN/AANGOAngioDynamicsN/AN/AN/AN/AN/AATRSAntares PharmaN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ASRDXSurmodicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFIBAcutus MedicalN/A1.851.57ANGOAngioDynamicsN/A2.211.40ATRSAntares Pharma0.103.082.87PLSEPulse BiosciencesN/A15.5815.58SRDXSurmodics0.275.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFIBAcutus Medical56.91%ANGOAngioDynamics89.43%ATRSAntares Pharma50.41%PLSEPulse Biosciences76.95%SRDXSurmodics96.63%Insider OwnershipCompanyInsider OwnershipAFIBAcutus Medical5.21%ANGOAngioDynamics5.40%ATRSAntares Pharma5.90%PLSEPulse Biosciences71.50%SRDXSurmodics8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFIBAcutus Medical34029.78 million28.23 millionOptionableANGOAngioDynamics76040.61 million38.41 millionOptionableATRSAntares Pharma201170.85 million160.77 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableSRDXSurmodics45014.30 million13.03 millionOptionableANGO, ATRS, AFIB, PLSE, and SRDX HeadlinesRecent News About These CompaniesSurmodics, Inc. (SRDX) stock price, news, quote & history - Yahoo FinanceJuly 3 at 9:00 PM | au.finance.yahoo.comFY2025 EPS Estimates for Surmodics Reduced by Zacks ResearchJuly 3 at 7:27 AM | marketbeat.comQ1 Earnings Estimate for Surmodics Issued By Zacks ResearchJuly 3 at 2:59 AM | americanbankingnews.comZacks Research Has Bearish Outlook for Surmodics Q1 EarningsJuly 2 at 8:44 AM | marketbeat.comCalifornia State Teachers Retirement System Boosts Stake in Surmodics, Inc. (NASDAQ:SRDX)June 8, 2025 | marketbeat.comQuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comWhy Is SurModics (SRDX) Up 6% Since Last Earnings Report?May 30, 2025 | zacks.comSurmodics, Ballinasloe, offers production operator opportunitiesMay 15, 2025 | advertiser.ieAAre Options Traders Betting on a Big Move in Surmodics Stock?May 2, 2025 | msn.comSRDX Stock Down Following Q2 Earnings Miss, Gross Margin ContractsMay 1, 2025 | zacks.comSurmodics stock takes another hit on Q2 miss and 2025 guidanceApril 30, 2025 | massdevice.comSurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to SayApril 30, 2025 | zacks.comSurModics (SRDX) Reports Q2 Loss, Misses Revenue EstimatesApril 30, 2025 | zacks.comSurmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial GuidanceApril 30, 2025 | businesswire.comA Look at Surmodics's Upcoming Earnings ReportApril 30, 2025 | benzinga.comSurmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30April 28, 2025 | businesswire.comResults Published From TRANSCEND Study of Surmodics SurVeil DCBApril 23, 2025 | evtoday.comESurmodics publishes TRANSCEND trial dataApril 22, 2025 | markets.businessinsider.comSurmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated BalloonApril 22, 2025 | businesswire.comIllinois joins FTC suit to block GTCR’s takeover of SurmodicsApril 17, 2025 | chicagobusiness.comCAG Ellison Joins Suit to Block Surmodics AcquisitionApril 17, 2025 | tcbmag.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANGO, ATRS, AFIB, PLSE, and SRDX Company DescriptionsAcutus Medical NASDAQ:AFIB$0.0020 0.00 (0.00%) As of 07/3/2025Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.AngioDynamics NASDAQ:ANGO$9.59 +0.20 (+2.13%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$9.59 0.00 (0.00%) As of 07/3/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Antares Pharma NASDAQ:ATRSAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.Pulse Biosciences NASDAQ:PLSE$14.80 -0.52 (-3.42%) As of 07/3/2025 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Surmodics NASDAQ:SRDX$29.98 +0.99 (+3.40%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
